loading
Marker Therapeutics Inc stock is traded at $3.14, with a volume of 22,048. It is down -1.26% in the last 24 hours and down -15.14% over the past month. Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
See More
Previous Close:
$3.18
Open:
$3.11
24h Volume:
22,048
Relative Volume:
0.64
Market Cap:
$28.37M
Revenue:
-
Net Income/Loss:
$-8.24M
P/E Ratio:
-2.0128
EPS:
-1.56
Net Cash Flow:
$-16.44M
1W Performance:
-10.29%
1M Performance:
-15.14%
6M Performance:
-23.19%
1Y Performance:
+20.77%
1-Day Range:
Value
$2.9101
$3.20
1-Week Range:
Value
$2.8205
$3.44
52-Week Range:
Value
$2.4377
$6.1568

Marker Therapeutics Inc Stock (MRKR) Company Profile

Name
Name
Marker Therapeutics Inc
Name
Phone
(713) 400-6400
Name
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Name
Employee
8
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MRKR's Discussions on Twitter

Compare MRKR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
MRKR 3.00 28.37M 0 -8.24M -16.44M -1.56
VRTX 447.61 115.74B 10.63B -479.80M -1.35B 13.33
REGN 744.50 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.97 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.87 24.49B 3.30B -501.07M 1.03B 11.54

Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-25-21 Initiated Piper Sandler Overweight
Mar-19-21 Initiated Cantor Fitzgerald Overweight
May-12-20 Downgrade Piper Sandler Overweight → Neutral
May-30-19 Initiated ROTH Capital Buy
Mar-01-19 Initiated Janney Buy
Dec-03-18 Upgrade Piper Jaffray Neutral → Overweight
View All

Marker Therapeutics Inc Stock (MRKR) Latest News

pulisher
Nov 19, 2024

Hematopoietic Stem Cell Transplantation Market to Exhibit - openPR

Nov 19, 2024
pulisher
Nov 18, 2024

Silence Therapeutics' Zerlasiran Shows 90% Reduction in Key Heart Disease Marker | SLN Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 17, 2024
pulisher
Nov 14, 2024

Precision Optics Receives Initial Production Order for Single-Use Ophthalmic Program - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Marker Therapeutics Secures $4M NIH Grants, Reports Promising MT-601 Trial Progress | MRKR Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Marker Therapeutics Inc (MRKR) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 12, 2024

Alterity's Advanced Brain Imaging Breakthrough Reveals New MSA Disease Progression Marker | ATHE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 07, 2024

Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma - OncLive

Nov 07, 2024
pulisher
Nov 07, 2024

MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors - OncLive

Nov 07, 2024
pulisher
Oct 23, 2024

US Penny Stocks To Consider In October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - India Shorts

Oct 21, 2024
pulisher
Oct 16, 2024

Kids Marker Market to hit USD 257.4 million by 2032, says Global Market Insights Inc. - Yahoo Finance

Oct 16, 2024
pulisher
Oct 01, 2024

PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - PR Newswire UK

Oct 01, 2024
pulisher
Sep 30, 2024

Omega Therapeutics stock hits 52-week low at $1.2 - Investing.com

Sep 30, 2024
pulisher
Sep 26, 2024

AML cell therapy trials to watch in 2024 targeting GvHD - Yahoo Finance

Sep 26, 2024
pulisher
Sep 23, 2024

Markforged (NYSE:MKFG) Sees Unusually-High Trading Volume - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Top 3 Health Care Stocks That May Explode This Month - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines

Sep 23, 2024
pulisher
Sep 23, 2024

On Tuesday’s show: Medical 'Blind Spots' - WJCT NEWS

Sep 23, 2024
pulisher
Sep 23, 2024

ProShare Advisors LLC Has $47.68 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire

Sep 23, 2024
pulisher
Sep 23, 2024

ProShare Advisors LLC Sells 43,073 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

AI Is Poised to Influence Several Areas of Cancer Care With Some Fine-Tuning - OncLive

Sep 23, 2024
pulisher
Sep 21, 2024

Meiji Yasuda Asset Management Co Ltd. Has $580,000 Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Washington Journal: Dr. Marty Makary Discusses His Book "Blind Spots" & Health Care in the U.S. - C-SPAN

Sep 21, 2024
pulisher
Sep 20, 2024

Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 20, 2024
pulisher
Sep 20, 2024

Hematopoietic Stem Cell Transplantation Global Market Report 2024 Size and Forecast - WhaTech

Sep 20, 2024
pulisher
Sep 20, 2024

Edgestream Partners L.P. Invests $1.67 Million in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Moderna Inc [NASDAQ: MRNA] Sees Decrease in Stock Value - Knox Daily

Sep 20, 2024
pulisher
Sep 20, 2024

Hematopoietic stem cell transplantation (HSCT) Market to See - openPR

Sep 20, 2024
pulisher
Sep 20, 2024

Down 13% in 1 Day, Is Moderna Stock in Trouble? - The Motley Fool

Sep 20, 2024
pulisher
Sep 20, 2024

Quest Partners LLC Trims Stock Position in Marsh & McLennan Companies, Inc. (NYSE:MMC) - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 19, 2024
pulisher
Sep 18, 2024

Parallel Advisors LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail

Sep 18, 2024
pulisher
Sep 17, 2024

Dr. Marty Makary Talks "Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health" - The Clay Travis & Buck Sexton Show

Sep 17, 2024
pulisher
Sep 17, 2024

Acadian Asset Management LLC Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Dai ichi Life Insurance Company Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors - OncLive

Sep 16, 2024
pulisher
Sep 14, 2024

Wedbush Securities Inc. Invests $393,000 in First Trust NASDAQ BuyWrite Income ETF (NASDAQ:FTQI) - Defense World

Sep 14, 2024
pulisher
Sep 14, 2024

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Recommendation of “Buy” from Analysts - Defense World

Sep 14, 2024
pulisher
Sep 14, 2024

United Parks & Resorts Inc. (NYSE:PRKS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Sep 14, 2024
pulisher
Sep 12, 2024

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan

Sep 12, 2024
pulisher
Sep 05, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in - GlobeNewswire

Sep 05, 2024
pulisher
Aug 30, 2024

Short Interest in Solventum Co. (NYSE:SOLV) Drops By 17.8% - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

VanEck Pharmaceutical ETF (NASDAQ:PPH) Short Interest Down 17.3% in August - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

MYR Group Inc. (NASDAQ:MYRG) Short Interest Update - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

Phillips 66 (NYSE:PSX) Shares Sold by Allspring Global Investments Holdings LLC - Defense World

Aug 30, 2024
pulisher
Aug 30, 2024

Bank of New York Mellon Corp Acquires 36,810 Shares of SEI Investments (NASDAQ:SEIC) - Defense World

Aug 30, 2024
pulisher
Aug 28, 2024

Anthem Blue Cross and Blue Shield unveils a new historic marker in Columbus - Yahoo Finance

Aug 28, 2024

Marker Therapeutics Inc Stock (MRKR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):